Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Long-term outcomes of subjects with EBV driven PTLD following solid organ or allogeneic HCT treated with tabelecleucel

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 19.12.19
Views: 154
Rating:

Dr Sarah Nikiforow - Dana-Farber Cancer Institute, Boston, USA

Dr Sarah Nikiforow speaks to ecancer at the 2019 ASH meeting in Orlando about a study looking at long-term outcomes of subjects with EBV (Epstein-Barr virus) driven PTLD (post-transplant lymphoproliferative disorder) following solid organ or allogeneic HCT treated with tabelecleucel.

She explains that the safety was reported from 61 patients enrolled in the trial and was proved to be incredibly safe during the infusion process and only 9% of patients had grade 3 or higher treatment related SAEs.

Dr Nikiforow reports that in the solid organ and allogeneic HCT groups the overall response rates were 80% and 50% respectively.

Related videos

follow us

Biosimilar Medicines Core Principles and Communication


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation